Healthcare, Regulatory and Reimbursement Landscape – Spain

Aug. 9, 2012 - PRLog -- The population of Spain has increased at a CAGR of 1.3% from 2005-2010. Immigrants account for approximately 20% of the total population. As in most other developed countries, Spain also has an increasing elderly population. Approximately 20% of the total population was above the age of 65 in 2010. Due to the increasing elderly population and the associated disease burden, the demand for healthcare services is expected to grow; however, that will increase the healthcare cost burden and pose a challenge to the economic growth of the country. The unemployment rate in Spain is the highest in the eurozone. Unemployment was 21% according to second quarter figures released in July 2011. The high unemployment rate has increased the country’s spending and therefore debt, which was pegged at $743 billion in 2010.

The major causes of the high unemployment rate are:
•   High unemployment benefits provided by the government, which do not put a lot of pressure on those unemployed to find work again.
•   Wage rigidity, due to labor legislation and weak coordination between unions and employers.
•   The high rate of dropouts after secondary education

In 2010, the Spanish pharmaceutical market was ranked fifth in Western Europe. Pricing in Spain is strictly regulated as the average price of the pharmaceutical products is lower than in most of the developed markets, such as the US and Germany. However, the prices of new drugs are in line with other European countries.

The pharmaceutical market was valued at approximately $18.9 billion in 2010. From 2005-2010, the market grew at a CAGR of 7.9% and is projected to grow at a CAGR of approximately 3.9% from 2011- 2020. In Spain, the right to health protection and healthcare for all citizens is provided under Article 43 of the Spanish Constitution of 1978.

For Sample Pages, please click or add the below link to your browser:
http://www.globalmarketsdirect.com/SamplePdfRequest.aspx?...

In Spain, the market for drugs is dominated by prescription medicines. in 2004-2005, in value terms, the prescription drugs accounted for 92%, and in volume terms 85%, of the total sales. It is estimated that new pharmaceutical medicines and biologic medicines will be entering the market in the next few years. Another important characteristic of the Spanish pharmaceutical market is the limited penetration of generic drugs. in Spain, the market share of generics is half of the overall share of generics in the European Union.

In Spain, due to the reference price system, the prices of branded drugs are kept very close to the reference price, which becomes the cap for reimbursement. Therefore, branded drug prices come closer to generic drug prices. This causes the generic drugs to lose their main price advantage.

Global Markets Direct, the industry analysis specialist, has released its new report, “Healthcare, Regulatory and Reimbursement Landscape - Spain”. The report is an essential source of information and an analysis on the healthcare, regulatory and reimbursement landscape of Spain. The report identifies the key trends in the healthcare market of Spain. The report also provides insights on the demographic, regulatory, reimbursement landscape and healthcare infrastructure of Spain. Most importantly, the report provides valuable insights on the trends and segmentation of pharmaceutical and medical devices market.

For further details, please click or add the below link to your browser:
http://www.globalmarketsdirect.com/Report.aspx?ID=Healthc...

Visit our report store: http://www.globalmarketsdirect.com

For more details contact:
pressreleases@globalmarketsdirect.com
North America:    +1 646 395 5477
Europe:        +44 207 753 4299
           +44 1204 543 533
Asia Pacific:       +91 40 6616 6782